Table of Content

1 Report Overview
1.1 Gefitinib Definition
1.2 Market by Type
1.2.1 Global Gefitinib Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 10 Tables/Box
1.2.3 30 Tables/Box
1.2.4 90 Tables/Box
1.3 Market Segment by Application
1.3.1 Global Gefitinib Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Gefitinib Sales
2.1 Global Gefitinib Revenue Estimates and Forecasts 2018-2034
2.2 Global Gefitinib Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Gefitinib Revenue by Region
2.3.1 Global Gefitinib Revenue by Region (2018-2024)
2.3.2 Global Gefitinib Revenue by Region (2024-2034)
2.4 Global Gefitinib Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Gefitinib Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Gefitinib Sales Quantity by Region
2.6.1 Global Gefitinib Sales Quantity by Region (2018-2024)
2.6.2 Global Gefitinib Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Gefitinib Sales Quantity by Manufacturers
3.1.1 Global Gefitinib Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Gefitinib Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Gefitinib Sales in 2022
3.2 Global Gefitinib Revenue by Manufacturers
3.2.1 Global Gefitinib Revenue by Manufacturers (2018-2024)
3.2.2 Global Gefitinib Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Gefitinib Revenue in 2022
3.3 Global Gefitinib Sales Price by Manufacturers
3.4 Global Key Players of Gefitinib, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Gefitinib Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Gefitinib, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Gefitinib, Product Offered and Application
3.8 Global Key Manufacturers of Gefitinib, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Gefitinib Sales Quantity by Type
4.1.1 Global Gefitinib Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Gefitinib Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Gefitinib Sales Quantity Market Share by Type (2018-2034)
4.2 Global Gefitinib Revenue by Type
4.2.1 Global Gefitinib Historical Revenue by Type (2018-2024)
4.2.2 Global Gefitinib Forecasted Revenue by Type (2024-2034)
4.2.3 Global Gefitinib Revenue Market Share by Type (2018-2034)
4.3 Global Gefitinib Price by Type
4.3.1 Global Gefitinib Price by Type (2018-2024)
4.3.2 Global Gefitinib Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Gefitinib Sales Quantity by Application
5.1.1 Global Gefitinib Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Gefitinib Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Gefitinib Sales Quantity Market Share by Application (2018-2034)
5.2 Global Gefitinib Revenue by Application
5.2.1 Global Gefitinib Historical Revenue by Application (2018-2024)
5.2.2 Global Gefitinib Forecasted Revenue by Application (2024-2034)
5.2.3 Global Gefitinib Revenue Market Share by Application (2018-2034)
5.3 Global Gefitinib Price by Application
5.3.1 Global Gefitinib Price by Application (2018-2024)
5.3.2 Global Gefitinib Price Forecast by Application (2024-2034)
6 North America
6.1 North America Gefitinib Sales by Company
6.1.1 North America Gefitinib Revenue by Company (2018-2024)
6.1.2 North America Gefitinib Sales Quantity by Company (2018-2024)
6.2 North America Gefitinib Market Size by Type
6.2.1 North America Gefitinib Sales Quantity by Type (2018-2034)
6.2.2 North America Gefitinib Revenue by Type (2018-2034)
6.3 North America Gefitinib Market Size by Application
6.3.1 North America Gefitinib Sales Quantity by Application (2018-2034)
6.3.2 North America Gefitinib Revenue by Application (2018-2034)
6.4 North America Gefitinib Market Size by Country
6.4.1 North America Gefitinib Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Gefitinib Revenue by Country (2018-2034)
6.4.3 North America Gefitinib Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Gefitinib Sales by Company
7.1.1 Europe Gefitinib Sales Quantity by Company (2018-2024)
7.1.2 Europe Gefitinib Revenue by Company (2018-2024)
7.2 Europe Gefitinib Market Size by Type
7.2.1 Europe Gefitinib Sales Quantity by Type (2018-2034)
7.2.2 Europe Gefitinib Revenue by Type (2018-2034)
7.3 Europe Gefitinib Market Size by Application
7.3.1 Europe Gefitinib Sales Quantity by Application (2018-2034)
7.3.2 Europe Gefitinib Revenue by Application (2018-2034)
7.4 Europe Gefitinib Market Size by Country
7.4.1 Europe Gefitinib Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Gefitinib Revenue by Country (2018-2034)
7.4.3 Europe Gefitinib Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Gefitinib Sales by Company
8.1.1 China Gefitinib Sales Quantity by Company (2018-2024)
8.1.2 China Gefitinib Revenue by Company (2018-2024)
8.2 China Gefitinib Market Size by Type
8.2.1 China Gefitinib Sales Quantity by Type (2018-2034)
8.2.2 China Gefitinib Revenue by Type (2018-2034)
8.3 China Gefitinib Market Size by Application
8.3.1 China Gefitinib Sales Quantity by Application (2018-2034)
8.3.2 China Gefitinib Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Gefitinib Sales by Company
9.1.1 APAC Gefitinib Sales Quantity by Company (2018-2024)
9.1.2 APAC Gefitinib Revenue by Company (2018-2024)
9.2 APAC Gefitinib Market Size by Type
9.2.1 APAC Gefitinib Sales Quantity by Type (2018-2034)
9.2.2 APAC Gefitinib Revenue by Type (2018-2034)
9.3 APAC Gefitinib Market Size by Application
9.3.1 APAC Gefitinib Sales Quantity by Application (2018-2034)
9.3.2 APAC Gefitinib Revenue by Application (2018-2034)
9.4 APAC Gefitinib Market Size by Region
9.4.1 APAC Gefitinib Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Gefitinib Revenue by Region (2018-2034)
9.4.3 APAC Gefitinib Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Gefitinib Sales by Company
10.1.1 Middle East, Africa and Latin America Gefitinib Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Gefitinib Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Gefitinib Market Size by Type
10.2.1 Middle East, Africa and Latin America Gefitinib Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Gefitinib Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Gefitinib Market Size by Application
10.3.1 Middle East, Africa and Latin America Gefitinib Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Gefitinib Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Gefitinib Market Size by Country
10.4.1 Middle East, Africa and Latin America Gefitinib Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Gefitinib Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Gefitinib Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 AstraZeneca Gefitinib Products and Services
11.1.5 AstraZeneca Gefitinib SWOT Analysis
11.1.6 AstraZeneca Recent Developments
11.2 Qilu Pharmaceutical
11.2.1 Qilu Pharmaceutical Company Information
11.2.2 Qilu Pharmaceutical Overview
11.2.3 Qilu Pharmaceutical Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Qilu Pharmaceutical Gefitinib Products and Services
11.2.5 Qilu Pharmaceutical Gefitinib SWOT Analysis
11.2.6 Qilu Pharmaceutical Recent Developments
11.3 Natco Pharma
11.3.1 Natco Pharma Company Information
11.3.2 Natco Pharma Overview
11.3.3 Natco Pharma Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Natco Pharma Gefitinib Products and Services
11.3.5 Natco Pharma Gefitinib SWOT Analysis
11.3.6 Natco Pharma Recent Developments
11.4 Celon Laboratories
11.4.1 Celon Laboratories Company Information
11.4.2 Celon Laboratories Overview
11.4.3 Celon Laboratories Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Celon Laboratories Gefitinib Products and Services
11.4.5 Celon Laboratories Gefitinib SWOT Analysis
11.4.6 Celon Laboratories Recent Developments
11.5 Hetero Drugs
11.5.1 Hetero Drugs Company Information
11.5.2 Hetero Drugs Overview
11.5.3 Hetero Drugs Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 Hetero Drugs Gefitinib Products and Services
11.5.5 Hetero Drugs Gefitinib SWOT Analysis
11.5.6 Hetero Drugs Recent Developments
11.6 Dr Reddy's Laboratories
11.6.1 Dr Reddy's Laboratories Company Information
11.6.2 Dr Reddy's Laboratories Overview
11.6.3 Dr Reddy's Laboratories Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Dr Reddy's Laboratories Gefitinib Products and Services
11.6.5 Dr Reddy's Laboratories Gefitinib SWOT Analysis
11.6.6 Dr Reddy's Laboratories Recent Developments
11.7 Zuventus Healthcare
11.7.1 Zuventus Healthcare Company Information
11.7.2 Zuventus Healthcare Overview
11.7.3 Zuventus Healthcare Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Zuventus Healthcare Gefitinib Products and Services
11.7.5 Zuventus Healthcare Gefitinib SWOT Analysis
11.7.6 Zuventus Healthcare Recent Developments
11.8 United Biotech
11.8.1 United Biotech Company Information
11.8.2 United Biotech Overview
11.8.3 United Biotech Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.8.4 United Biotech Gefitinib Products and Services
11.8.5 United Biotech Gefitinib SWOT Analysis
11.8.6 United Biotech Recent Developments
11.9 Panacea Biotec
11.9.1 Panacea Biotec Company Information
11.9.2 Panacea Biotec Overview
11.9.3 Panacea Biotec Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.9.4 Panacea Biotec Gefitinib Products and Services
11.9.5 Panacea Biotec Gefitinib SWOT Analysis
11.9.6 Panacea Biotec Recent Developments
11.10 Cipla
11.10.1 Cipla Company Information
11.10.2 Cipla Overview
11.10.3 Cipla Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.10.4 Cipla Gefitinib Products and Services
11.10.5 Cipla Gefitinib SWOT Analysis
11.10.6 Cipla Recent Developments
11.11 Glenmark Pharmaceuticals
11.11.1 Glenmark Pharmaceuticals Company Information
11.11.2 Glenmark Pharmaceuticals Overview
11.11.3 Glenmark Pharmaceuticals Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.11.4 Glenmark Pharmaceuticals Gefitinib Products and Services
11.11.5 Glenmark Pharmaceuticals Recent Developments
11.12 Nobel Ilac Sanayii Ve Ticaret
11.12.1 Nobel Ilac Sanayii Ve Ticaret Company Information
11.12.2 Nobel Ilac Sanayii Ve Ticaret Overview
11.12.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.12.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Products and Services
11.12.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments
11.13 Accure Labs
11.13.1 Accure Labs Company Information
11.13.2 Accure Labs Overview
11.13.3 Accure Labs Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.13.4 Accure Labs Gefitinib Products and Services
11.13.5 Accure Labs Recent Developments
11.14 Cadila Pharmaceuticals
11.14.1 Cadila Pharmaceuticals Company Information
11.14.2 Cadila Pharmaceuticals Overview
11.14.3 Cadila Pharmaceuticals Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.14.4 Cadila Pharmaceuticals Gefitinib Products and Services
11.14.5 Cadila Pharmaceuticals Recent Developments
11.15 Ethypharm
11.15.1 Ethypharm Company Information
11.15.2 Ethypharm Overview
11.15.3 Ethypharm Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.15.4 Ethypharm Gefitinib Products and Services
11.15.5 Ethypharm Recent Developments
11.16 Flagship Biotech International
11.16.1 Flagship Biotech International Company Information
11.16.2 Flagship Biotech International Overview
11.16.3 Flagship Biotech International Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.16.4 Flagship Biotech International Gefitinib Products and Services
11.16.5 Flagship Biotech International Recent Developments
11.17 Globela Pharma
11.17.1 Globela Pharma Company Information
11.17.2 Globela Pharma Overview
11.17.3 Globela Pharma Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.17.4 Globela Pharma Gefitinib Products and Services
11.17.5 Globela Pharma Recent Developments
11.18 Jodas Expoim
11.18.1 Jodas Expoim Company Information
11.18.2 Jodas Expoim Overview
11.18.3 Jodas Expoim Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.18.4 Jodas Expoim Gefitinib Products and Services
11.18.5 Jodas Expoim Recent Developments
11.19 Nishchay Pharmaceuticals
11.19.1 Nishchay Pharmaceuticals Company Information
11.19.2 Nishchay Pharmaceuticals Overview
11.19.3 Nishchay Pharmaceuticals Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.19.4 Nishchay Pharmaceuticals Gefitinib Products and Services
11.19.5 Nishchay Pharmaceuticals Recent Developments
11.20 Sichuan Xieli Pharmaceutical
11.20.1 Sichuan Xieli Pharmaceutical Company Information
11.20.2 Sichuan Xieli Pharmaceutical Overview
11.20.3 Sichuan Xieli Pharmaceutical Gefitinib Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.20.4 Sichuan Xieli Pharmaceutical Gefitinib Products and Services
11.20.5 Sichuan Xieli Pharmaceutical Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Gefitinib Value Chain Analysis
12.2 Gefitinib Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Gefitinib Production Mode & Process
12.4 Gefitinib Sales and Marketing
12.4.1 Gefitinib Sales Channels
12.4.2 Gefitinib Distributors
12.5 Gefitinib Customers
13 Market Dynamics
13.1 Gefitinib Industry Trends
13.2 Gefitinib Market Drivers
13.3 Gefitinib Market Challenges
13.4 Gefitinib Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Gefitinib Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of 10 Tables/Box
Table 3. Major Manufacturers of 30 Tables/Box
Table 4. Major Manufacturers of 90 Tables/Box
Table 5. Global Gefitinib Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Gefitinib Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 7. Global Gefitinib Revenue by Region (2018-2024) & (US$ Million)
Table 8. Global Gefitinib Revenue Market Share by Region (2018-2024)
Table 9. Global Gefitinib Revenue by Region (2024-2034) & (US$ Million)
Table 10. Global Gefitinib Revenue Market Share by Region (2024-2034)
Table 11. Global Gefitinib Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Pcs)
Table 12. Global Gefitinib Sales by Region (2018-2024) & (K Pcs)
Table 13. Global Gefitinib Sales Market Share by Region (2018-2024)
Table 14. Global Gefitinib Sales by Region (2024-2034) & (K Pcs)
Table 15. Global Gefitinib Sales Market Share by Region (2024-2034)
Table 16. Global Gefitinib Sales Quantity by Manufacturers (2018-2024) & (K Pcs)
Table 17. Global Gefitinib Sales Quantity Share by Manufacturers (2018-2024)
Table 18. Global Gefitinib Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 19. Global Gefitinib Revenue Share by Manufacturers (2018-2024)
Table 20. Global Gefitinib Price by Manufacturers 2018-2024 (USD/Pcs)
Table 21. Global Key Players of Gefitinib, Industry Ranking, 2021 VS 2022
Table 22. Global Gefitinib Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 23. Global Gefitinib by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Gefitinib as of 2022)
Table 24. Global Key Manufacturers of Gefitinib, Manufacturing Base Distribution and Headquarters
Table 25. Global Key Manufacturers of Gefitinib, Product Offered and Application
Table 26. Global Key Manufacturers of Gefitinib, Date of Enter into This Industry
Table 27. Mergers & Acquisitions, Expansion Plans
Table 28. Global Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 29. Global Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 30. Global Gefitinib Sales Quantity Share by Type (2018-2024)
Table 31. Global Gefitinib Sales Quantity Share by Type (2024-2034)
Table 32. Global Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 33. Global Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 34. Global Gefitinib Revenue Share by Type (2018-2024)
Table 35. Global Gefitinib Revenue Share by Type (2024-2034)
Table 36. Gefitinib Price by Type (2018-2024) & (USD/Pcs)
Table 37. Global Gefitinib Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 38. Global Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 39. Global Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 40. Global Gefitinib Sales Quantity Share by Application (2018-2024)
Table 41. Global Gefitinib Sales Quantity Share by Application (2024-2034)
Table 42. Global Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 43. Global Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 44. Global Gefitinib Revenue Share by Application (2018-2024)
Table 45. Global Gefitinib Revenue Share by Application (2024-2034)
Table 46. Gefitinib Price by Application (2018-2024) & (USD/Pcs)
Table 47. Global Gefitinib Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 48. North America Gefitinib Revenue by Company (2018-2024) & (US$ Million)
Table 49. North America Gefitinib Sales Quantity by Company (2018-2024) & (K Pcs)
Table 50. North America Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 51. North America Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 52. North America Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 53. North America Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 54. North America Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 55. North America Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 56. North America Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 57. North America Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 58. North America Gefitinib Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 59. North America Gefitinib Revenue by Country (2018-2024) & (US$ Million)
Table 60. North America Gefitinib Revenue by Country (2024-2034) & (US$ Million)
Table 61. North America Gefitinib Sales Quantity by Country (2018-2024) & (K Pcs)
Table 62. North America Gefitinib Sales Quantity by Country (2024-2034) & (K Pcs)
Table 63. Europe Gefitinib Sales Quantity by Company (2018-2024) & (K Pcs)
Table 64. Europe Gefitinib Revenue by Company (2018-2024) & (US$ Million)
Table 65. Europe Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 66. Europe Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 67. Europe Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 68. Europe Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 69. Europe Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 70. Europe Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 71. Europe Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 72. Europe Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 73. Europe Gefitinib Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 74. Europe Gefitinib Revenue by Country (2018-2024) & (US$ Million)
Table 75. Europe Gefitinib Revenue by Country (2024-2034) & (US$ Million)
Table 76. Europe Gefitinib Sales Quantity by Country (2018-2024) & (K Pcs)
Table 77. Europe Gefitinib Sales Quantity by Country (2024-2034) & (K Pcs)
Table 78. China Gefitinib Sales Quantity by Company (2018-2024) & (K Pcs)
Table 79. China Gefitinib Revenue by Company (2018-2024) & (US$ Million)
Table 80. China Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 81. China Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 82. China Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 83. China Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 84. China Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 85. China Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 86. China Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 87. China Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 88. APAC Gefitinib Sales Quantity by Company (2018-2024) & (K Pcs)
Table 89. APAC Gefitinib Revenue by Company (2018-2024) & (US$ Million)
Table 90. APAC Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 91. APAC Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 92. APAC Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 93. APAC Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 94. APAC Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 95. APAC Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 96. APAC Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 97. APAC Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 98. APAC Gefitinib Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 99. APAC Gefitinib Revenue by Region (2018-2024) & (US$ Million)
Table 100. APAC Gefitinib Revenue by Region (2024-2034) & (US$ Million)
Table 101. APAC Gefitinib Sales Quantity by Region (2018-2024) & (K Pcs)
Table 102. APAC Gefitinib Sales Quantity by Region (2024-2034) & (K Pcs)
Table 103. Middle East, Africa and Latin America Gefitinib Sales Quantity by Company (2018-2024) & (K Pcs)
Table 104. Middle East, Africa and Latin America Gefitinib Revenue by Company (2018-2024) & (US$ Million)
Table 105. Middle East, Africa and Latin America Gefitinib Sales Quantity by Type (2018-2024) & (K Pcs)
Table 106. Middle East, Africa and Latin America Gefitinib Sales Quantity by Type (2024-2034) & (K Pcs)
Table 107. Middle East, Africa and Latin America Gefitinib Revenue by Type (2018-2024) & (US$ Million)
Table 108. Middle East, Africa and Latin America Gefitinib Revenue by Type (2024-2034) & (US$ Million)
Table 109. Middle East, Africa and Latin America Gefitinib Sales Quantity by Application (2018-2024) & (K Pcs)
Table 110. Middle East, Africa and Latin America Gefitinib Sales Quantity by Application (2024-2034) & (K Pcs)
Table 111. Middle East, Africa and Latin America Gefitinib Revenue by Application (2018-2024) & (US$ Million)
Table 112. Middle East, Africa and Latin America Gefitinib Revenue by Application (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Gefitinib Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 114. Middle East, Africa and Latin America Gefitinib Revenue by Country (2018-2024) & (US$ Million)
Table 115. Middle East, Africa and Latin America Gefitinib Revenue by Country (2024-2034) & (US$ Million)
Table 116. Middle East, Africa and Latin America Gefitinib Sales Quantity by Country (2018-2024) & (K Pcs)
Table 117. Middle East, Africa and Latin America Gefitinib Sales Quantity by Country (2024-2034) & (K Pcs)
Table 118. AstraZeneca Company Information
Table 119. AstraZeneca Description and Overview
Table 120. AstraZeneca Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 121. AstraZeneca Gefitinib Product and Services
Table 122. AstraZeneca Gefitinib SWOT Analysis
Table 123. AstraZeneca Recent Developments
Table 124. Qilu Pharmaceutical Company Information
Table 125. Qilu Pharmaceutical Description and Overview
Table 126. Qilu Pharmaceutical Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 127. Qilu Pharmaceutical Gefitinib Product and Services
Table 128. Qilu Pharmaceutical Gefitinib SWOT Analysis
Table 129. Qilu Pharmaceutical Recent Developments
Table 130. Natco Pharma Company Information
Table 131. Natco Pharma Description and Overview
Table 132. Natco Pharma Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 133. Natco Pharma Gefitinib Product and Services
Table 134. Natco Pharma Gefitinib SWOT Analysis
Table 135. Natco Pharma Recent Developments
Table 136. Celon Laboratories Company Information
Table 137. Celon Laboratories Description and Overview
Table 138. Celon Laboratories Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 139. Celon Laboratories Gefitinib Product and Services
Table 140. Celon Laboratories Gefitinib SWOT Analysis
Table 141. Celon Laboratories Recent Developments
Table 142. Hetero Drugs Company Information
Table 143. Hetero Drugs Description and Overview
Table 144. Hetero Drugs Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 145. Hetero Drugs Gefitinib Product and Services
Table 146. Hetero Drugs Gefitinib SWOT Analysis
Table 147. Hetero Drugs Recent Developments
Table 148. Dr Reddy's Laboratories Company Information
Table 149. Dr Reddy's Laboratories Description and Overview
Table 150. Dr Reddy's Laboratories Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 151. Dr Reddy's Laboratories Gefitinib Product and Services
Table 152. Dr Reddy's Laboratories Gefitinib SWOT Analysis
Table 153. Dr Reddy's Laboratories Recent Developments
Table 154. Zuventus Healthcare Company Information
Table 155. Zuventus Healthcare Description and Overview
Table 156. Zuventus Healthcare Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 157. Zuventus Healthcare Gefitinib Product and Services
Table 158. Zuventus Healthcare Gefitinib SWOT Analysis
Table 159. Zuventus Healthcare Recent Developments
Table 160. United Biotech Company Information
Table 161. United Biotech Description and Overview
Table 162. United Biotech Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 163. United Biotech Gefitinib Product and Services
Table 164. United Biotech Gefitinib SWOT Analysis
Table 165. United Biotech Recent Developments
Table 166. Panacea Biotec Company Information
Table 167. Panacea Biotec Description and Overview
Table 168. Panacea Biotec Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 169. Panacea Biotec Gefitinib Product and Services
Table 170. Panacea Biotec Gefitinib SWOT Analysis
Table 171. Panacea Biotec Recent Developments
Table 172. Cipla Company Information
Table 173. Cipla Description and Overview
Table 174. Cipla Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 175. Cipla Gefitinib Product and Services
Table 176. Cipla Gefitinib SWOT Analysis
Table 177. Cipla Recent Developments
Table 178. Glenmark Pharmaceuticals Company Information
Table 179. Glenmark Pharmaceuticals Description and Overview
Table 180. Glenmark Pharmaceuticals Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 181. Glenmark Pharmaceuticals Gefitinib Product and Services
Table 182. Glenmark Pharmaceuticals Recent Developments
Table 183. Nobel Ilac Sanayii Ve Ticaret Company Information
Table 184. Nobel Ilac Sanayii Ve Ticaret Description and Overview
Table 185. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 186. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product and Services
Table 187. Nobel Ilac Sanayii Ve Ticaret Recent Developments
Table 188. Accure Labs Company Information
Table 189. Accure Labs Description and Overview
Table 190. Accure Labs Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 191. Accure Labs Gefitinib Product and Services
Table 192. Accure Labs Recent Developments
Table 193. Cadila Pharmaceuticals Company Information
Table 194. Cadila Pharmaceuticals Description and Overview
Table 195. Cadila Pharmaceuticals Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 196. Cadila Pharmaceuticals Gefitinib Product and Services
Table 197. Cadila Pharmaceuticals Recent Developments
Table 198. Ethypharm Company Information
Table 199. Ethypharm Description and Overview
Table 200. Ethypharm Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 201. Ethypharm Gefitinib Product and Services
Table 202. Ethypharm Recent Developments
Table 203. Flagship Biotech International Company Information
Table 204. Flagship Biotech International Description and Overview
Table 205. Flagship Biotech International Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 206. Flagship Biotech International Gefitinib Product and Services
Table 207. Flagship Biotech International Recent Developments
Table 208. Globela Pharma Company Information
Table 209. Globela Pharma Description and Overview
Table 210. Globela Pharma Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 211. Globela Pharma Gefitinib Product and Services
Table 212. Globela Pharma Recent Developments
Table 213. Jodas Expoim Company Information
Table 214. Jodas Expoim Description and Overview
Table 215. Jodas Expoim Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 216. Jodas Expoim Gefitinib Product and Services
Table 217. Jodas Expoim Recent Developments
Table 218. Nishchay Pharmaceuticals Company Information
Table 219. Nishchay Pharmaceuticals Description and Overview
Table 220. Nishchay Pharmaceuticals Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 221. Nishchay Pharmaceuticals Gefitinib Product and Services
Table 222. Nishchay Pharmaceuticals Recent Developments
Table 223. Sichuan Xieli Pharmaceutical Company Information
Table 224. Sichuan Xieli Pharmaceutical Description and Overview
Table 225. Sichuan Xieli Pharmaceutical Gefitinib Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2024)
Table 226. Sichuan Xieli Pharmaceutical Gefitinib Product and Services
Table 227. Sichuan Xieli Pharmaceutical Recent Developments
Table 228. Key Raw Materials Lists
Table 229. Raw Materials Key Suppliers Lists
Table 230. Gefitinib Distributors List
Table 231. Gefitinib Customers List
Table 232. Gefitinib Market Trends
Table 233. Gefitinib Market Drivers
Table 234. Gefitinib Market Challenges
Table 235. Gefitinib Market Restraints
Table 236. Research Programs/Design for This Report
Table 237. Key Data Information from Secondary Sources
Table 238. Key Data Information from Primary Sources
List of Figures
Figure 1. Gefitinib Product Picture
Figure 2. Global Gefitinib Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Gefitinib Market Share by Type in 2022 & 2034
Figure 4. 10 Tables/Box Product Picture
Figure 5. 30 Tables/Box Product Picture
Figure 6. 90 Tables/Box Product Picture
Figure 7. Global Gefitinib Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 8. Global Gefitinib Market Share by Application in 2022 & 2034
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Drug Center
Figure 12. Other
Figure 13. Gefitinib Report Years Considered
Figure 14. Global Gefitinib Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 15. Global Gefitinib Revenue 2018-2034 (US$ Million)
Figure 16. Global Gefitinib Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 17. Global Gefitinib Sales Quantity 2018-2034 (K Pcs)
Figure 18. Global Gefitinib Sales Quantity Market Share by Region (2018-2024)
Figure 19. Global Gefitinib Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Gefitinib Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 21. North America Gefitinib Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Gefitinib Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 23. Europe Gefitinib Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Gefitinib Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 25. China Gefitinib Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Gefitinib Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 27. APAC Gefitinib Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Gefitinib Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 29. Middle East, Africa and Latin America Gefitinib Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Gefitinib Sales Quantity in 2022
Figure 31. The Top 10 and Top 5 Players Market Share by Gefitinib Revenue in 2022
Figure 32. Gefitinib Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 33. Global Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Gefitinib Revenue Market Share by Type (2018-2034)
Figure 35. Global Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Gefitinib Revenue Market Share by Application (2018-2034)
Figure 37. North America Gefitinib Revenue Market Share by Company in 2022
Figure 38. North America Gefitinib Sales Quantity Market Share by Company in 2022
Figure 39. North America Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Gefitinib Revenue Market Share by Type (2018-2034)
Figure 41. North America Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Gefitinib Revenue Market Share by Application (2018-2034)
Figure 43. North America Gefitinib Revenue Share by Country (2018-2034)
Figure 44. North America Gefitinib Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Gefitinib Sales Quantity Market Share by Company in 2022
Figure 48. Europe Gefitinib Revenue Market Share by Company in 2022
Figure 49. Europe Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Gefitinib Revenue Market Share by Type (2018-2034)
Figure 51. Europe Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Gefitinib Revenue Market Share by Application (2018-2034)
Figure 53. Europe Gefitinib Revenue Share by Country (2018-2034)
Figure 54. Europe Gefitinib Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 56. France Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 60. China Gefitinib Sales Quantity Market Share by Company in 2022
Figure 61. China Gefitinib Revenue Market Share by Company in 2022
Figure 62. China Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Gefitinib Revenue Market Share by Type (2018-2034)
Figure 64. China Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Gefitinib Revenue Market Share by Application (2018-2034)
Figure 66. APAC Gefitinib Sales Quantity Market Share by Company in 2022
Figure 67. APAC Gefitinib Revenue Market Share by Company in 2022
Figure 68. APAC Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Gefitinib Revenue Market Share by Type (2018-2034)
Figure 70. APAC Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Gefitinib Revenue Market Share by Application (2018-2034)
Figure 72. APAC Gefitinib Revenue Share by Region (2018-2034)
Figure 73. APAC Gefitinib Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 78. India Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Gefitinib Sales Quantity Market Share by Company in 2022
Figure 80. Middle East, Africa and Latin America Gefitinib Revenue Market Share by Company in 2022
Figure 81. Middle East, Africa and Latin America Gefitinib Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Gefitinib Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Gefitinib Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Gefitinib Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Gefitinib Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Gefitinib Revenue Share by Country (2018-2034)
Figure 87. Brazil Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Gefitinib Revenue (2018-2034) & (US$ Million)
Figure 92. Gefitinib Value Chain
Figure 93. Gefitinib Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed